Laboratories, Hoechst Japan Limited, Saitama,2 Japan Cefotaxime, a new semisynthetic cephalosporin derivative, showed a broad spectrum of antibacterial activity against clinically isolated strains of grampositive and gram-negative bacteria. This cephalosporin was slightly less active than cefazolin against Staphylococcus aureus but 4 to 300 times as active as carbenicillin against gram-negative organisms, including Pseudomonas aeruginosa, Pseudomonas cepacia, Enterobacter cloacae, and Serratia marcescens. Cefotaxime was the most active compound against members of the Enterobacteriaceae and 20-to 100-fold more active than cefoxitin against the indole-positive Proteus group. The minimal bactericidal concentrations of the compound were identical to, or two times higher than, the minximal inhibitory concentrations against Escherichia coli and P. aeruginosa and four times higher against S. marcescens. A reduction of inoculum size decreased greatly the miniimal inhibitory and bactericidal concentrations of cefotaxime against E. coli, P. aeruginosa, and S. marcescens. The antibiotic was very stable to penicillinase and cephalosporinase produced by gram-negative bacteria, including Proteus vulgaris.
Many cephalosporins with broad antibacterial spectra have been in clinical use for the treatment of a wide range of bacterial infections. Recently, however, the effectiveness of the existing cephalosporins has been shown to be limited; there has been a steady increase in clinical infections caused by gram-negative bacteria resistant to 8l-lactam antibiotics, e.g., Pseudomonas spp., Enterobacter spp., Serratia marcescens, and indole-positive Proteus spp., which have been reported to produce ,B-lactamase (11, 12, 25) . Much effort has been expended in developing broad-spectrum antibiotics with resistance to the enzyme. Cefoxitin, cefotiam, and cefuroxime have been semisynthesized, but they are still ineffective against some strains of Enterobacter spp. and Pseudomonas spp. (13, 15, 17, 26, 27) . Cefotaxime, a new cephalosporin, has been reported to have a broad antimicrobial spectrum (1, 2, 4, 6, 7, 14, 23, 24, 28, 29) and to be a potent inhibitor of ,B-lactamase and stable in the presence of the enzyme (5). The present study deals with the in vitro antimicrobial activity and ,B-lactamase stability of the compound using clinical isolates stocked in this laboratory. MATERIALS Media. Heart infusion (HI) agar and brain heart infusion (BHI) agar were used. BHI broth and antibiotic medium 3 (ABM 3) were used. Other media used were medium B, peptone water, and nutrient agar containing bromothymol blue and lactose. Medium B consisted of 2 g of yeast extract, 10 g of polypeptone, 8 g of Na2HPO4 12H20, 2 g of KH2PO4,
1.2 g of (NH4)2SO4, 2 g of glucose, 0.4 g of MgSO4.
7H20, and 1,000 ml of purified water, and the medium was adjusted to pH 7.4 . Peptone water consisted of 10 g of polypeptone, 5 g of NaCl, and 1,000 ml of purified water. For the dilution of cell suspensions, ABM 3 and buffered saline containing gelatin (3) were used.
ANTIMICROB. AGENTS CHEMOTHER.
Peptone water containing of 0.3% KNO3 was used for Pseudomonas strains. BHI broth was used for Staphylococcus pyogenes; BHI broth containing 10 ,ug of hemin per ml and 2 jig of nicotinamide adenine dinucleotide per ml was used for Haemophilus influenzae, and peptone water was used for the rest of the strains. The inoculun was prepared by diluting the cultures in buffered saline containing gelatin solution. Endpoints were scored after 18 h of incubation at 370C. The MICs recorded, after 18 h of incubation at 370C, were the lowest concentrations of antibiotic that inhibited the visible growth of bacteria.
Determination of minimal bactericidal concentrations. Each organism was grown overnight in ABM 3, and the overnight culture was inoculated at the final concentration of 104 cells/ml into ABM 3 containing a serial twofold dilution of a drug. Minimal bactericidal concentrations (MBCs) were measured by spotting a 5-pl portion from sample broth culture onto antibiotic-free bromothymol blue agar and incubating the culture at 37°C for 18 h. They were defined as the lowest concentrations of drug that produced no colonies on agar plates.
Determination of bactericidal activity. Overnight culture in ABM 3 at 37°C was inoculated into freshly prepared ABM 3 and shake-cultured at 37°C for 2 h. When the organisms had grown to a density of approximately 104 cells/ml, antibiotics at concentrations ranging from one-fourth to four times the MIC value were added to the culture. Samples were taken at appropriate time intervals and inoculated on drugfree bromothymol blue agar plates, and the numbers of colonies were counted after 18 h of incubation at 370C.
Effects of inoculum size on MICs and MBCs. Each test organism was grown in ABM 3 at 370C overnight. Tenfold serial dilutions of the culture in ABM 3 were inoculated into ABM 3 containing twofold serial dilutions of the drug, and the MICs and MBCs were measured after 18 h of incubation at 370C. ,8-Lactamase preparation. Escherichia coli W3630 (Rms212+), E. coli W3630 (Rms213+), Pseudomonas aeruginosa MIA259 (Rms139+), and Klebsiellapneumoniae GN69 were employed as the strains producing penicillinase (PCase) (11, 12, 22) . Six strains were used as the producers of cephalosporinase (CSase). These comprised E. coli GN5482, P. aeruginosa GN918, Proteus vulgaris GN76, Enterobacter cloacae GN7471, Citrobacter freundii GN?46, and Proteus morganii GN5406. Overnight BHI broth cultures were diluted 10-fold in 250 ml of medium B. Cultures of the PCase producers were harvested by centrifugation after incubation in a shaker at 370C for 5 h. Cultures of the CSase producers were incubated in a sh.ker at 370C; after 3 h of incubation, penicillin G was added as an inducer, and the bacteria were harvested after another 2 h of incubation. All the harvested organisms were washed twice with 50 mM phosphate buffer (pH 7.0) and suspended in 5 ml of phosphate buffer. The cells were disrupted by sonic treatment by an ultrasonicator at 30-s intervals for 10 min in an ice bath. The sonicated cells were centrifuged for 30 min at 40C at 9,000 x g, and the supernatant was used as the source of fi-lactamase.
Assay of P-Lactamase. ,B-Lactamase activity was determined by the spectrophotometric method (18, 20) 
RESULTS
Antimicrobial spectrum. The MIC distribution of cefotaxime and four other antibiotics for standard strains of bacteria is shown in Table  1 . Against Staphylococcus aureus, cefotaxime was slightly less active than cefazolin and cefotiam and as active as cefuroxime and cefoxitin. However, against gram-negative bacteria, cefotaxime showed a much higher degree of activity than any of the other four antibiotics.
Antimicrobial activity against clinical isolates. The in vitro antimicrobial activity of c3fotaxime against gram-positive and gram-negative organisms was compared with those of cefuroxime, cefotiam, cefoxitin, cefazolin, and carbenicillin. Table 2 shows the concentrations of antibiotics required to inhibit the growth of 50 and 90% of the total number of strains examined (MIC50 and M1C0o). Against S. aureus, cefotaxime was slightly less active than cefotiam and cefazolin but as active as or a little more active than cefuroxime, cefoxitin, and carbenicillin. Cefotaxime, however, showed a higher degree of activity than cefuroxime, cefotiam, cefoxitin, and cefazolin against gram-negative bacteria, including E. coli, K. pneumoniae, Salmonella spp., and Proteus mirabilis. Cefotaxime was 25-to 140-fold more active than cefuroxime, cefoxitin, and cefazolin against E. coli, K. pneumoniae, and P. mirabilis, and 10 to 25 times as active as the cefoxitin and cefazolin against Salmonella spp. Furthermore, cefotaxime was quite active against species usually reported as being cephalosporin resistant (indole-positive Proteus spp., Enterobacter spp., S. marcescens, and Pseudomonas spp.). The activity of cefotaxime was greater than those of cefoxitin and carbenicillin against indole-positive Proteus strains; the compound was approximately 100-fold more active against P. morganii and Proteus rettgeri and 20-to 50-fold more active against P. vulgaris and Proteus inconstans than cefoxitin. The concentration of cefotaxime required for 100% inhibition of Proteus spp. strains was as low as 25 ,ug/ml. In additiorn. cefotaxime exhibited a high (Fig. 1) (Fig. 2) , and all of the drugs inhibited the growth of cells after 20 h of incubation. These three concentrations were found to be equivalent to MICs obtained by broth dilution assay.
Susceptibility to fi-lactamase. The relative rates of hydrolysis of the six cephalosporins and of penicillin G and cephaloridine are presented in Table 4 . Cefotaxime, cefuroxime, and cefoxitin were stable to PCase produced by K. pneumoniae, R-mediated PCases, and CSases produced by E. coli GN5482, P. aeruginosa GN918, E. cloacae GN7471, C. freundii GN346, and P. morganii GN5406. To CSase produced by P. vulgaris GN76, cefotaxime was less stable than cefoxitin, but was 3.5-fold more stable than cephaloridine and 2-to 13-fold more resistant than cefuroxime, cefotiam, and cefazolin.
DISCUSSION
Many antibiotics with a broad antimicrobial spectrum have been in clinical use in Japan for the treatment of a wide range of bacteria infection. Recently, however, the effectiveness of the existing antibiotics has been shown to be limited. This limited effectiveness has been shown to be due in part to the production of f)-lactamases (11, 12, 22, 25) . Much effort has been expended in an attempt to develop broad-spectrum antibiotics with resistance to the enzyme. As a result, recently introduced cephalosporins, such as cefoxitin, cefotiam, and cefuroxime, have possessed some in vitro activity against isolates of Enterobeter and indole-positive Proteus, but not Pseudomonas (13, 14, 17, 26, 27 CE.
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The MIC and MBC of cefotaxime were af- 
